Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers

(BUSINESS WIRE)--May 30, 2008 - -0-
WHAT: Pfizer Oncology will host a journalist briefing at the American

      Society of Clinical Oncology (ASCO) Annual Meeting on Sunday,

      June 1, 2008, highlighting key data presentations from a variety

      of compounds in several difficult-to-treat tumor types,

      including renal cell carcinoma and non-small cell lung cancer.

      Leading oncology physicians and researchers will present study

      results and offer their professional perspective.


WHO:  Robert Figlin, M.D., F.A.C.P., City of Hope

      Abstract #5024: "Overall survival with sunitinib versus

      interferon (IFN)-alfa as first-line treatment of metastatic

      renal cell carcinoma (mRCC)"


      Antonio Gualberto, M.D., Ph.D., Pfizer Global Research and

      Development

      Abstract #10501: "Safety, pharmacokinetics and preliminary

      activity of the anti-IGF-1R antibody CP-751,871 in

      sarcoma patients"


      Daniel Karp, M.D., M.D. Anderson Cancer Center

      Abstract #8000: "Characterization of NSCLC patients responding

      to anti-IGF-1R therapy"


      Pasi A. Janne, M.D., Ph.D., Dana-Farber Cancer Institute

      Abstract #8027, Poster #8: "Preliminary activity and safety

      results from a phase I clinical trial of PF-00299804, an

      irreversible pan-HER inhibitor, in patients (pts) with NSCLC"


      John H. Sampson, M.D., Ph.D., Duke University Medical Center

      Abstract #2061: "Effect of EGFRvIII-targeted vaccine (CDX-110)

      on immune response and TTP when given with simultaneous standard

      and continuous temozolomide in patients with GBM"


WHEN:  Sunday, June 1, 2008 at 6:00 PM (CT)


WHERE: Westin River North - Grand Ballroom A&B

       320 N. Dearborn Avenue

       Chicago, IL 60610

      (312) 744-1900

Contact

Rx Mosaic Health
Jacqueline Karis
212-336-7534
347-267-9353
jkaris@rxmosaic.com

Posted: May 2008

View comments

Hide
(web1)